title: Premixed Insulin Analogue Compared with Basal-Plus Regimen for Inpatient Glycemic Control.
abstract: No previous studies have investigated the use of a premixed insulin analogue in a hospital setting.
  
  
  
  To compare the efficacy and safety of treatment with premixed insulin analogue (insulin lispro mix 75/25, LM75/25) with the basal-plus regimen with insulin glargine in hospitalized patients with type 2 diabetes (T2D).
  
  
  
  A randomized clinical trial in hospitalized patients with T2D and glucose >140 mg/dL on admission was performed. A total of 54 patients were randomized to receive insulin LM75/25 or glargine. In both groups, a correction dose of lispro was administered before meals. Insulin dose was adjusted to obtain a mean blood glucose (BG) between 100 and 140 mg/dL.
  
  
  
  Improvement in the mean BG after the first day of treatment was similar in both groups (P = 0.470). Glycemic control at the end of follow-up was similar between the group with insulin LM75/25 (131.3 ± 28.4 mg/dL) and insulin glargine (143.8 ± 32.5 mg/dL, P = 0.153). The aim of a BG concentration of <140 mg/dL was obtained in 72% of the patients in the premixed insulin analogue group and 56% of patients in the basal-plus group (P = 0.239). There was no difference in the frequency of hypoglycemia between groups (7 vs. 10, P = 0.529).
  
  
  
  Results of this trial indicate that the use of a premixed insulin analogue is as effective and safe as the basal-plus regimen to achieve glycemic control.
authors.affiliation: 1 Departamento de Medicina Interna, Hospital de Especialidades , Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, Mexico City, Mexico .
authors.forename: Abraham Edgar
authors.initials: AE
authors.lastname: Gracia-Ramos
authors.affiliation: 2 División de Investigación en Salud, Hospital de Especialidades , Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, Mexico City, Mexico .
authors.forename: María Del Pilar
authors.initials: MD
authors.lastname: Cruz-Domínguez
authors.affiliation: 3 Laboratorio de Medicina de Conservación, Escuela Superior de Medicina, Instituto Politécnico Nacional , Mexico City, Mexico .
authors.forename: Eduardo Osiris
authors.initials: EO
authors.lastname: Madrigal-Santillán
authors.affiliation: 3 Laboratorio de Medicina de Conservación, Escuela Superior de Medicina, Instituto Politécnico Nacional , Mexico City, Mexico .
authors.forename: José Antonio
authors.initials: JA
authors.lastname: Morales-González
authors.affiliation: 4 Escuela Superior de Ciencias Biológicas, Instituto Politécnico Nacional , Mexico City, Mexico .
authors.forename: Eduardo
authors.initials: E
authors.lastname: Madrigal-Bujaidar
authors.affiliation: 3 Laboratorio de Medicina de Conservación, Escuela Superior de Medicina, Instituto Politécnico Nacional , Mexico City, Mexico .
authors.forename: José Leopoldo
authors.initials: JL
authors.lastname: Aguilar-Faisal
mesh_terms: D000368:Aged; D001786:Blood Glucose / Q000032:analysis*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000627:therapeutic use*; D000069036:Insulin Glargine / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D000069036:Insulin Glargine
keywords: Hyperglycemia; Inpatient; Insulin lispro mix 75/25; Premixed insulin analogue; Type 2 diabetes